Immuno-oncology

#Cancer #Cancer research #Immuno-oncology #Immunotherapy #Molecular Biology #Oncology #Rare disease

Podcast: The next steps in the fight against cancer

This is the latest episode of the free DDW podcast, “The next steps in the fight against cancer”. It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “Accelerating research: the path forward for treating rare cancers” and “Inside combination… Read More

#News

#CAR-T #Drug discovery #eBook #Immuno-oncology

Latest eBook: Innovation in immuno-oncology

This 28-page eBook sponsored by Twist Bioscience features insights and expert opinions on the latest advancements occurring in immuno-oncology and drug discovery. Read this eBook to learn about: The challenges and opportunities facing CAR-T cell therapies Targeting GPCRs in cancer drug discovery The immuno-oncology landscape and its many pathways Access… Read More

#News

#CAR-T #Drug development #Immuno-oncology

Advancements driving drug discovery in immuno-oncology

This latest 28 page eBook sponsored by Twist Bioscience features insights and expert opinions on the latest advancements occurring in immuno-oncology and drug discovery. Read this eBook to learn about: The challenges and opportunities facing CAR-T cell therapies Targeting GPCRs in cancer drug discovery The immuno-oncology landscape and its many… Read More

#DDW eBooks #Intelligence

#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #mRNA #mRNA-based vaccines

Merck and Moderna to jointly develop personalised cancer vaccine 

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna.   mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk… Read More

#Cancer Research #News

Basel map
#Biologics / Biotechnology #Cancer immunotherapy #Immuno-oncology #Market reporting #Oncology #Start-ups

Basel: a centre for ground-breaking oncology 

Listen to this article on the DDW podcast: Dr Stephan Emmerth and Paul Eschmann, Basel Area Business & Innovation, explain the benefits of being based in Basel – the talent pool, global players, academic institutions and investors, for example.  Companies specialising in oncology R&D… Read More

#Exclusive Content #Market Reports

RNA vaccine
#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA

Merck and Moderna to develop personalised cancer vaccine

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year. “We have been collaborating with Merck… Read More

#Cancer Research #News #Trending News

Melanoma or skin cancer
#Immuno-oncology #Melanoma #Oncology

T cell therapy for melanoma shows promise 

New trial data has shown that using a patient’s own immune cells could be a powerful immunotherapy for metastatic melanoma, an aggressive skin cancer.  The TIL (tumour-infiltrating lymphocytes) trial compared T cell therapy to standard immunotherapy with the checkpoint inhibitor ipilimumab.  The results of the… Read More

#Cancer Research #News

ESMO Congress, Paris
#Cancer research #Immuno-oncology #Oncology

GSK to share oncology findings at ESMO

GSK will present its latest gynaecological cancer research at the European Society for Medical Oncology (ESMO) Congress 2022 (September 9-13). The company will share positive trial data on its gynaecological cancer treatments Zejula (niraparib) and Jemperli (dostarlimab), as well as early-stage research in immuno-oncology and real-world evidence assessing treatment patterns… Read More

#Cancer Research #News

#Acquisition #Business #Immuno-oncology #Pharma

GSK to acquire Sierra Oncology in £1.5bn deal 

GlaxoSmithKline (GSK) is to acquire biopharmaceutical company Sierra Oncology in a deal worth £1.5 billion, the company has announced.   Sierra Oncology  Sierra Oncology is a late-stage company focused on targeted therapies for the treatment of rare forms of cancer. The company’s lead asset, momelotinib, is being… Read More

#Business & Investment #News

#FDA #Immuno-oncology #Regulatory

Noxopharm granted ODD for lead oncology drug  

Australian biotech Noxopharm has received an Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for its lead oncology candidate in the treatment of soft tissue sarcoma.   Noxopharm’s Veyonda is a formulation of a first-in-class, dual-acting oncotoxic and immuno-oncology molecule known as idronoxil. Idronoxil is… Read More

#News

#Immuno-oncology #Immunotherapy #T-Cells

The evolving immuno-oncology landscape 

Dr Ian Walters, Chief Executive Officer and Director of Portage Biotech, shares how to find the path of least resistance through the immuno-oncology landscape.  Our bodies are naturally trained to identify and remove abnormal cells, including those that are cancerous. Under normal circumstances, a person’s immune system detects proteins on the surface of cancer cells and targets them for elimination. The… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Biologics #Drug development #Drug discovery #Immuno-oncology #Monoclonal antibodies

The potential of small molecules and biologics for new therapeutics 

Listen to this article on the DDW Podcast: Dr Seth Lederman is a physician-scientist, entrepreneur, and CEO of Tonix Pharmaceuticals. He talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.  Since its formation in 2011, Tonix Pharmaceuticals… Read More

#Business & Investment #Exclusive Content #News

#Cancer immunotherapy #Flow Cytometry #Immuno-oncology #Webinar

Free webinar addresses bottlenecks in immuno-oncology therapies 

Within our drug discovery world, unless we have contact with clinical settings, it is easy to lose sight that our expertise, time, laboratory instruments, software, reagents, tools, workflows and procedures etc. are ultimately designed for the benefit of real-life patients.  Deriving Context from Immunological Data with Advanced Flow Cytometry… Read More

#News

#Biologics / Biotechnology #Cancer immunotherapy #Drug discovery #Flow Cytometry #Immuno-oncology #Webinar

Webinar offers insight into pharmacological reactions

Dr Nina Senutovitch, Senior Scientist, Sartorius, notes that more efficient and powerful tools are critical for furthering the development of highly target-specific immunotherapies, such as adoptive cell transfer therapies. These include Chimeric Antigen Receptor T cells (CAR-T), that harness an individual’s own immune system to attack cancerous cells. … Read More

#News #Trending News

#Biopharma #Cancer research #Cell therapy #Drug discovery #Flow Cytometry #Immuno-oncology #Immunology #Webinar

Learn about immunophenotyping and advanced cell function assays

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of… Read More

#News